Sickle Cell Disease news and research updates
Research readouts, treatment and access decisions, and community updates for people living with sickle cell disease and the people who care for them — each one dated, with a link to the original source where there is one.
444 articlesFree, no login required
Looking for earlier coverage? Browse the news archive.
Cost-Effectiveness of Sickle Cell Transplant vs Gene Therapy
Summary Question This study analyzed the cost-effectiveness of three treatment strategies for sickle cell disease (SCD): standard care (SOC), gene therapy (GT), and…
Stem cell transplantation found to be more cost-effective than gene therapy for sickle cell disease
Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment…
Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns
June 2 (Reuters) - Shares of Fulcrum Therapeutics (FULC.O) , opens new tab plunged 52% on Tuesday after the company said it would abandon development of its experimental…
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI , June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. ( Correctseq ), a…
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
The drug, pociredir, was being developed as an oral treatment for sickle-cell disease, an inherited blood disorder that can cause pain, anemia, organ damage and reduced life…
Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease
Abstract Renin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may exacerbate anemia in…
Emerging concepts in sickle cell disease acute chest syndrome
Abstract Sickle cell disease (SCD) is a globally prevalent inherited hemoglobinopathy marked by chronic hemolysis, vaso-occlusion, and systemic inflammation, leading to…
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global withdrawal on…
Prevalence of Alloantibodies in Sickle Cell Disease and its Impact in Low-Resource Countries
Abstract Alloimmunisation is a notorious dilemma in blood transfusion intervention therapy, especially in low-resource countries, and studies have shown that individuals with…
Evaluating the Diagnostic Performance of AI and Machine Learning in Sickle Cell Disease Detection: A Systematic Review
Abstract Sickle cell disease (SCD) is a major global health burden, and early, accurate diagnosis is critical for effective management. Conventional diagnostic methods are often…
Govt paying special attention to anaemia, sickle cell anaemia in tribal areas, says Health Minister
Health Minister Y. Satya Kumar on Friday said that the State government is committed to strengthening healthcare infrastructure and improving medical services in remote tribal…
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in…